Free for academic non-profit institutions. Other users need a Commercial license
The integral membrane protein encoded by this gene is a lysophosphatidic acid (LPA) receptor from a group known as EDG receptors. These receptors are members of the G protein-coupled receptor superfamily. Utilized by LPA for cell signaling, EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion. Many transcript variants encoding a few different isoforms have been identified for this gene. [provided by RefSeq, Oct 2020]
LPAR1 (Lysophosphatidic Acid Receptor 1) is a Protein Coding gene. Diseases associated with LPAR1 include Pulmonary Fibrosis and Spinal Stenosis. Among its related pathways are Signaling by GPCR and Myometrial Relaxation and Contraction Pathways. Gene Ontology (GO) annotations related to this gene include G protein-coupled receptor activity and phospholipid binding. An important paralog of this gene is LPAR2.
GeneHancer (GH) Identifier | GH Type | GH Score |
GH Sources | Gene Association Score | Total Score | TSS distance (kb) | Number of Genes Away | Size (kb) | Transcription Factor Binding Sites |
Gene Targets |
---|---|---|---|---|---|---|---|---|---|---|
GH09J111033 | Promoter/Enhancer | 2.2 | EPDnew Ensembl ENCODE CraniofacialAtlas dbSUPER | 255.7 | +2.1 | 2098 | 7 | ZBTB10 CTCF ZIC2 TRIM22 MAFF ZNF341 SMC3 KLF9 SMARCA5 BCL11B | LPAR1 HSALNG0073672 SVEP1 PTGR1 RF00017-7811 MUSK | |
GH09J111021 | Promoter/Enhancer | 0.9 | EPDnew Ensembl | 250.4 | +16.1 | 16102 | 1.8 | MAFF ZNF316 NFE2 MAFK MAFG BACH1 IKZF1 IKZF2 RELB EMSY | LPAR1 HSALNG0073672 RF00017-7811 MUSK | |
GH09J110999 | Promoter/Enhancer | 0.5 | EPDnew dbSUPER | 250.3 | +39.5 | 39512 | 0.1 | LPAR1 RF00017-7811 HSALNG0073672 MUSK | ||
GH09J111040 | Promoter | 0.4 | EPDnew | 250.7 | -1.6 | -1587 | 0.1 | JUND | LPAR1 HSALNG0073672 piR-38051-301 OR2K2 | |
GH09J111160 | Enhancer | 1.2 | VISTA Ensembl ENCODE CraniofacialAtlas | 23.7 | -124.2 | -124175 | 5.2 | NR2C1 MAFK JUND SP7 NANOG MNT CEBPB FOS | LPAR1 piR-38352-580 HSALNG0073677 ENSG00000227531 LOC105376219 OR2K2 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0001965 | G-protein alpha-subunit binding | IEA | -- |
GO:0004930 | G protein-coupled receptor activity | IEA,IBA | 21873635 |
GO:0005515 | protein binding | IPI | 19306925 |
GO:0005543 | phospholipid binding | IEA | -- |
GO:0008289 | lipid binding | IEA | -- |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005737 | cytoplasm | IBA | 21873635 |
GO:0005768 | endosome | IEA,IDA | 19306925 |
GO:0005886 | plasma membrane | IEA,TAS | -- |
GO:0005887 | integral component of plasma membrane | TAS,ISS | -- |
GO:0009986 | cell surface | IEA,IDA | 19306925 |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Peptide ligand-binding receptors | ||
2 | Signaling by GPCR | ||
3 | RET signaling | ||
4 | Gap junction | ||
5 | Salmonella infection (KEGG) |
Symbol | External ID(s) | Details |
---|---|---|
PALM2AKAP2 | ||
ADCY6 | ||
ADGRE5 | ||
ADGRL3 | ||
ADRA1A |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000187 | activation of MAPK activity | IEA | -- |
GO:0007165 | signal transduction | IEA | -- |
GO:0007186 | G protein-coupled receptor signaling pathway | IEA,TAS | -- |
GO:0007189 | adenylate cyclase-activating G protein-coupled receptor signaling pathway | IBA | 21873635 |
GO:0007193 | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | ISS | -- |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
AM966 | Pharma | Antagonist | LPA1 antagonist, oral active, high affinity, selective, | 0 | ||
1-Oleoyl lysophosphatidic acid sodium salt | Pharma | Activates LPA receptor, Endogenous agonist of LPA1 and LPA2 | 0 | |||
GRI 977143 | Pharma | LPA2 receptor non-lipid agonist, Selective LPA2 receptor non-lipid agonist | 0 | |||
H2L 5765834 | Pharma | LPA1,3,5 antagonist | 0 | |||
H2L5186303 | Pharma | Potent and selective LPA2 receptor antagonist | 0 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
dioctanoy?àëlglycerol?àë pyrophos?àëphate |
|
Antagonist |
|
|||
LysoPA(0:0/16:0) |
|
|
||||
LysoPA(0:0/18:0) |
|
|
||||
LysoPA(0:0/18:1(9Z)) |
|
|
||||
LysoPA(0:0/18:2(9Z,12Z)) |
|
|
Compound | Action | Cas Number |
---|---|---|
1-Oleoyl lysophosphatidic acid sodium salt | Endogenous agonist of LPA1 and LPA2 | 325465-93-8 |
GRI 977143 | Selective LPA2 receptor non-lipid agonist | 325850-81-5 |
H2L 5765834 | LPA1,3,5 antagonist | 420841-84-5 |
H2L5186303 | Potent and selective LPA2 receptor antagonist | 139262-76-3 |
TC LPA5 4 | LPA5 receptor antagonist | 1393814-38-4 |
Compound | Action | Cas Number |
---|---|---|
1-Oleoyl lysophosphatidic acid sodium salt | Activates LPA receptor | 325465-93-8 |
AM095 | Potent LPA1 receptor antagonist | 1345614-59-6 |
AM-095 free base | Potent LPA1 receptor antagonist | 1228690-36-5 |
AM966 | LPA1 antagonist, oral active, high affinity, selective, | 1228690-19-4 |
GRI 977143 | LPA2 receptor non-lipid agonist | 325850-81-5 |
H2L 5765834 | 420841-84-5 | |
H2L5186303 | 139262-76-3 | |
Ki16198 | LPA antagonist | 355025-13-7 |
Ki16425 | LPA receptor antagonist | 355025-24-0 |
TC LPA5 4 | 1393814-38-4 |
ExUns: | 1 | ^ | 2 | ^ | 3a | · | 3b | · | 3c | · | 3d | · | 3e | ^ | 4 | ^ | 5 | ^ | 6a | · | 6b | ^ | 7 | ^ | 8 | ^ | 9a | · | 9b | ^ | 10 | ^ | 11a | · | 11b | · | 11c | ^ | 12 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | - | - | - | |||||||||||||||||||||||||||||||||||
SP2: | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
SP3: | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
SP4: | - | ||||||||||||||||||||||||||||||||||||||
SP5: | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
SP6: | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||
SP7: | |||||||||||||||||||||||||||||||||||||||
SP8: | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||
SP9: | - | - |
This gene was present in the common ancestor of chordates.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Chimpanzee (Pan troglodytes) |
Mammalia | LPAR1 30 31 |
|
OneToOne | |
Oppossum (Monodelphis domestica) |
Mammalia | LPAR1 31 |
|
OneToOne | |
Dog (Canis familiaris) |
Mammalia | LPAR1 30 31 |
|
OneToOne | |
Platypus (Ornithorhynchus anatinus) |
Mammalia | LPAR1 31 |
|
OneToOne | |
Cow (Bos Taurus) |
Mammalia | LPAR1 30 31 |
|
OneToOne | |
Mouse (Mus musculus) |
Mammalia | Lpar1 30 17 31 |
|
OneToOne | |
Rat (Rattus norvegicus) |
Mammalia | Lpar1 30 |
|
||
Chicken (Gallus gallus) |
Aves | LPAR1 30 31 |
|
OneToOne | |
Lizard (Anolis carolinensis) |
Reptilia | LPAR1 31 |
|
OneToOne | |
Tropical Clawed Frog (Silurana tropicalis) |
Amphibia | lpar1 30 |
|
||
African clawed frog (Xenopus laevis) |
Amphibia | edg2-A 30 |
|
||
Zebrafish (Danio rerio) |
Actinopterygii | lpar1 30 31 |
|
OneToOne |
SNP ID | Clinical significance and condition | Chr 09 pos | Variation | AA Info | Type |
---|---|---|---|---|---|
rs41279057 | Benign: not provided | 110,941,779(-) |
C/T NM_001401.5(LPAR1):c.435G>A (p.Glu145=) |
SYNONYMOUS | |
rs11542862 | - |
p.Asn77Ser |
Variant ID | Type | Subtype | PubMed ID |
---|---|---|---|
esv2667259 | CNV | deletion | 23128226 |
esv2738930 | CNV | deletion | 23290073 |
esv33480 | CNV | gain+loss | 17666407 |
esv3445715 | CNV | insertion | 20981092 |
esv3621475 | CNV | loss | 21293372 |
esv3621477 | CNV | gain | 21293372 |
esv3621478 | CNV | gain | 21293372 |
esv3621479 | CNV | loss | 21293372 |
nsv526335 | CNV | gain | 19592680 |
nsv527204 | CNV | loss | 19592680 |
nsv527998 | CNV | gain | 19592680 |
nsv831689 | CNV | gain | 17160897 |
Disorder | Aliases | PubMed IDs |
---|---|---|
pulmonary fibrosis |
|
|
spinal stenosis |
|
|
ovarian cancer |
|
|
tooth disease |
|
|
pulmonary fibrosis, idiopathic |
|
|